By Gabriel Alizaidy, MD, MS
Scientific Director, Maximus
PCAC stands for the Pharmacy Compounding Advisory Committee. It's not a peptide committee. It's not a secret FDA peptide task force. It's an FDA advisory committee that gives the agency scientific, technical, and medical advice on drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDA PCAC charter).
The reason the peptide worlds suddenly cares is because of the calendar.
On July 23 and 24, 2026, FDA says PCAC will discuss whether several peptide-related bulk drug substances should be considered for the 503A Bulks List, including BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon-related substances (FDA July 2026 PCAC meeting notice). Public comments are due by July 22, 2026, and anything submitted by July 9, 2026, gets in front of the committee (FDA July 2026 PCAC meeting notice).
That's a peptide greatest-hits list, and FDA didn't schedule it by accident. These are compounds that have lived for years in the gap between internet demand, provider interest, research-use marketing, offshore gray markets, and fights over compounding access.
PCAC is where that mess gets turned into one formal question: should this substance belong in traditional pharmacy compounding?
What PCAC actually does
The committee advises FDA on scientific, technical, and medical issues related to drug compounding and makes recommendations to the Commissioner of Food and Drugs (FDA PCAC charter).
Those recommendations are not law. FDA advisory committees give independent expert advice, and that advice is non-binding, so FDA can weigh it without being forced to follow it (FDA PCAC meeting page).
For 503A pharmacy compounding, FDA says a state-licensed physician or pharmacist can use a bulk drug substance only if it fits one of three lanes: it meets an applicable USP or NF monograph, it's a component of an FDA-approved drug product when no monograph exists, or it's on FDA's 503A Bulks List when neither of the first two applies (FDA 503A bulk-substances page). The peptides on this agenda fall in that third lane, so the Bulks List vote is the one that decides their path.
So PCAC isn't deciding whether a peptide is cool. It's helping FDA decide whether a nominated bulk drug substance fits a specific legal and quality framework for compounding.
Why the peptide world is hyped
It's not only that BPC-157 and TB-500 are familiar names. The July 2026 meeting hits the access question head on.
FDA's July 2026 agenda lists BPC-157-related substances for ulcerative colitis (a chronic inflammatory disease of the colon), KPV-related substances for wound healing and inflammatory conditions, TB-500-related substances for wound healing, MOTS-c-related substances for obesity and osteoporosis (weak, brittle bones that break easily), DSIP-related substances for opioid withdrawal, chronic insomnia, and narcolepsy (a disorder that causes sudden, uncontrollable sleep attacks), Semax-related substances for cerebral ischemia (reduced blood flow to the brain, the kind of damage behind a stroke), migraine, and trigeminal neuralgia (severe, stabbing facial nerve pain), and Epitalon-related substances for insomnia. (FDA July 2026 PCAC meeting notice).
That reads like a map of what the peptide world is curious about. Gut inflammation, wound healing, recovery, metabolism, sleep, neuroprotection, pain, aging.
The demand is obvious from the agenda itself. The regulatory question is narrower than the Internet version of it. FDA isn't asking whether biohackers like a peptide. It's asking whether the chemistry, the safety, the effectiveness evidence, and the history of compounding use support putting it on the 503A Bulks List.
FDA's 2019 final rule set four criteria for the 503A Bulks List: physical and chemical characterization, safety issues raised by use in compounded drug products, evidence of effectiveness or lack of it, and historical use in compounded drug products (FDA 503A final-rule Q&A).
That's where a lot of peptide enthusiasm stalls. An interesting mechanism, animal data, and anecdotes can generate a hypothesis. The compounding-policy question needs a different level of support.
Who is on PCAC
The committee is built around 12 voting members, including the chair, pulled from people who know pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties (FDA PCAC charter).
The charter says membership includes the National Association of Boards of Pharmacy, the United States Pharmacopeia, pharmacists with compounding expertise, physicians with a compounding background, and patient and public-health advocacy organizations (FDA PCAC charter).
The current FDA roster, updated December 1, 2025, lists the chair as vacant and shows three active voting members:
- Timothy D. Fensky, RPh, DPh, FACA, the National Association of Boards of Pharmacy representative
- Elizabeth Rebello, RPh, MD, FASA, CPPS, CMQ, with anesthesiology expertise
- Brian Serumaga, PhD, the United States Pharmacopeia representative
(FDA PCAC roster)
The same roster lists Donnette D. Staas, PhD, Vice President of Regulatory Strategy at Jazz Pharmaceuticals, as a non-voting industry representative, and Takyiah Stevenson, PharmD, as the committee's designated federal officer (FDA PCAC roster).
The roster also shows six vacancies, which is worth tracking, because the committee can bring in temporary voting members or consultants when it needs extra expertise or runs into quorum problems (FDA PCAC roster, FDA PCAC charter).
A standing committee won't have deep expertise in every molecule on the agenda, so for these peptides FDA can add temporary voting members who actually know the compounds.
The prior peptide meetings were not a victory lap
The reason this is worth watching is the same reason it's risky.
In December 2024, PCAC discussed AOD-9604-related substances, CJC-1295-related substances, and thymosin alpha-1-related substances for possible inclusion on the 503A Bulks List (FDA December 2024 PCAC minutes).
The committee voted 0-12 against placing AOD-9604 free base and AOD-9604 acetate on the list (FDA December 2024 PCAC minutes).
It voted unanimously against CJC-1295 free base and cited a lack of evidence for effectiveness (FDA December 2024 PCAC minutes).
For thymosin alpha-1, it voted 4-17 against both the free base and the acetate, with the minutes noting a lack of compelling evidence for clinical effectiveness and safety in the uses under review (FDA December 2024 PCAC minutes).
That doesn't doom every future peptide. It does show the committee will separate how popular a compound is from what the evidence says.
So watching PCAC tells you more than watching influencer clips. It's where the access argument has to get disciplined.
The safety-risk backdrop
FDA has already flagged a lot of peptide-related substances in its compounding safety-risk materials.
FDA's page on substances that may present significant safety risks lists GHRP-2, GHRP-6, ipamorelin acetate, kisspeptin-10, and ibutamoren mesylate among substances placed in category 2 under interim policies for 503A, 503B, or both (FDA significant safety-risk substances page).
The same page lists withdrawn nominated peptide-related substances, including BPC-157, CJC-1295, AOD-9604, KPV, MOTS-c, Semax, Epitalon, DSIP, GHK-Cu for injectable routes, TB-500, and thymosin alpha-1, with FDA repeatedly raising concerns about immunogenicity, peptide-related impurities, API characterization, limited safety information, or not enough human exposure data (FDA significant safety-risk substances page).
Take that seriously. FDA isn't only asking whether a molecule has an interesting mechanism. It's asking whether a compounded version can be characterized, manufactured, dosed, and monitored without creating unacceptable patient risk.
Peptides aren't all the same regulatory object. A short peptide with messy impurities, route-specific immunogenicity concerns, thin human data, and inconsistent source material is very different from how a clean marketing paragraph makes it sound.
My read
Pay attention to PCAC, but not because it guarantees a win for peptides. It doesn't.
December 2024 showed the opposite. Popularity, demand, a plausible mechanism, and years of gray-market use weren't enough on their own.
It's still worth watching because it forces the conversation to grow up. Peptides don't need more hype. They need better chemistry, better human data, better adverse-event tracking, better source accountability, and a clear line between an interesting biological signal and something appropriate for pharmacy compounding.
PCAC won't kill peptide curiosity. It will make it show its work.
The July 2026 meeting is worth following closely, not because every compound will clear the bar. The votes will show which arguments are starting to land, which ones aren't, and what kind of evidence the next phase of peptide medicine is going to need.
----
Disclaimer:
The contents of this article, including, but not limited to, text, graphics, images, and other information, is for information purposes only and does not constitute medical advice. The information contained herein is not a substitute for and should never be relied upon for professional medical advice. The content is not meant to be complete or exhaustive or to be applicable to any specific individual's medical condition. You should consult a licensed healthcare professional before starting any health protocol and seek the advice of your physician or other medical professional if you have questions or concerns about a medical condition. Always talk to your doctor about the risks and benefits of any treatment. Never disregard or delay seeking professional medical advice or treatment because of something you have read on this site. Maximus does not recommend, endorse, or make any representation about the efficacy, appropriateness, or suitability of any specific test, products, procedures, treatments, services, opinions, healthcare providers or other information contained herein. Maximus is not responsible for, nor will they bear any liability for, the content provided herein or any actions or outcomes resulting from or related to its use.
